What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025BloodOpen Access

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

View Full Paper

Ask AI

Bookmark

Progression-free survival improved significantly after deferasirox treatment in acute myeloid leukemia patients, with favorable implications for treatment.
Cox multivariate model estimates an HR of 2.27 for progression-free survival improvement in treated patients, indicating potential benefits.
Analysis included 41 patients treated with deferasirox and 82 controls matched through propensity score matching for confounding factors.
Importance of monitoring renal function during deferasirox treatment to manage potential adverse events related to therapy.

No takes yet. Share an insight, caveat, or question.

Prospective study demonstrates improved progression-free survival in AML patients after deferasirox treatment, suggesting iron chelation's relevance.

Huynh et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Prospective study demonstrates improved progression-free survival in AML patients after deferasirox treatment, suggesting iron chelation's relevance.